Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Non-Current Liabilities (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Other Non-Current Liabilities for 15 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $100000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $100000.0, a N/A change, with the full-year FY2023 number at $334000.0, changed N/A from a year prior.
  • Other Non-Current Liabilities was $100000.0 for Q3 2025 at NovaBay Pharmaceuticals, roughly flat from $100000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $561000.0 in Q4 2021 to a low of $100000.0 in Q1 2025.
  • A 5-year average of $272555.6 and a median of $334000.0 in 2023 define the central range for Other Non-Current Liabilities.
  • Biggest YoY gain for Other Non-Current Liabilities was 56.9% in 2025; the steepest drop was 56.9% in 2025.
  • NovaBay Pharmaceuticals' Other Non-Current Liabilities stood at $561000.0 in 2021, then plummeted by 39.04% to $342000.0 in 2022, then decreased by 2.34% to $334000.0 in 2023, then crashed by 30.54% to $232000.0 in 2024, then plummeted by 56.9% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Other Non-Current Liabilities are $100000.0 (Q3 2025), $100000.0 (Q2 2025), and $100000.0 (Q1 2025).